Throughout the first quarter, the Levocetirizine Dihydrochloride Prices inclined in North America on account of a continuous surge in inquiries from the pharmaceutical and healthcare sectors. Moreover, Overall inflation eased with the start of 2023 and after a significant prolonged labor shortage, owing to which the businesses in the US increased employment in January, and wages rose. Following February, the prices continued to display a similar trend and were recorded at USD 658000/MT CFR Los Angeles. Towards the termination of Q1, as inquiries from the downstream sector continued to rise, Inventories for Levocetirizine Dihydrochloride API remained low among the market players, which compelled them to focus on raising their shelves.
In the APAC region, Levocetirizine Dihydrochloride price particularly in China, demonstrate an incremented trend throughout the first quarter of 2023. In the month of January, Levocetirizine Dihydrochloride prices inclined in China because of a significant surge in domestic and international inquiries. The values rose at the same rate as they depreciated in December. Ease in logistic charges and a continuous surge in demand further supported the positive price trend of Levocetirizine Di-hydrochloride during the month of February, and the costs noted during this month were assembled at USD 618500/MT FOB Shanghai in China. With the end of March, the prices remained in the northward direction, compelling the manufacturers to raise their production activity and procure their shelves with downstream Levocetirizine Di-hydrochloride stocks.
In the First quarter of 2023, the market for Levocetirizine Di-Hydrochloride in Europe followed a similar path to that in the Asia Pacific. The market trend began well until the end of March. During the month of February, the prices achieved an assembly price of USD 672000/MT CFR Hamburg in Germany. Compared to the previous quarter, the inquiries from the domestic market inclined at a steady rate. Market players further focused on building their inventories for Levocetirizine Dihydrochloride API to prevent their shortage. In addition to that, the trend for this API at the end of the first quarter was supported by higher trade flow and simpler logistic expenses when compared to the prior quarter.
ChemAnalyst tackles the primary difficulty areas of the worldwide chemical, petroleum, pharmaceutical, and petrochemical industries, empowering decision-makers to make informed decisions. It examines and analyses geopolitical risks, environmental concerns, raw material availability, supply chain functioning, and technological disruption. It focuses on market volatility and guarantees that clients manage obstacles and hazards effectively and efficiently. ChemAnalyst's primary expertise has been data timeliness and accuracy, benefiting both local and global industries by tuning in to real-time data points to execute multibillion-dollar projects internationally.